Abstract:Objective: To investigate the effect of Nckα gene silencing on the malignant biological behavior of epithelial ovarian cancer cells. Methods: The expression characteristics of Nckα were analyzed in normal ovarian tissue sections,benign ovarian tissue sections and ovarian cancer tissue sections.The effects of Nckα silencing on ovarian cancer cell lines SKOV3 and OVCAR-3 were detected by immunofluorescence,cell invasion,migration,cell proliferation,subcutaneous xenograft animal model,and Western blot. Results: Nckα gene silencing could reduce the invasion and migration ability of ovarian cancer cells.The absorbance of SKOV3 and OVCAR3 cells with Nckα silence was significantly lower than that of the control group,and the absorbance of SKOV3 and OVCAR3 cells with Nckα overexpression was significantly higher than that of the control group (P<0.05).The tumor volume of Nckα silenced group was lower than that of control group (P<0.05).The protein expressions of PI3K P110 α,p70S6K,AKT and P-Akt in SKOV3 cells and OVCAR3 cells silenced by Nckα were significantly lower than those in the control group.The protein expressions of PI3K P110 α,p70S6K,AKT and P-Akt in SKOV3 cells and OVCAR3 cells with Nckα overexpression were significantly higher than those in the control group (P<0.05). Conclusion: Nckα gene silencing can reduce the proliferation and migration ability of epithelial ovarian cancer cells,and delay the growth rate of subcutaneous graft tumor,which may be related to the regulation of PI3K P110 α,p70S6K,AKT and P-Akt protein expression by Nckα gene silencing.
[1] Liu T,Wei Q,Jin J,et al.The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation[J].Nucleic Acids Research,2020,48(7):3816-3831. [2] Konstantinopoulos P A,Norquist B,Lacchetti C,et al.Germline and somatic tumor testing in epithelial ovarian cancer:ASCO guideline[J].Journal of Clinical Oncology,2020,38(11):1222-1245. [3] Vafadar A,Shabaninejad Z,Movahedpour A,et al.Quercetin and cancer:new insights into its therapeutic effects on ovarian cancer cells[J].Cell & bioscience,2020,10(1):1-17. [4] 尤敏,王福玲,王雅琦,等.脂肪间充质干细胞通过激活EZH2促进卵巢癌的增殖及侵袭[J].免疫学杂志,2019,35(6):45-52. [5] Izar B,Tirosh I,Stover E H,et al.A single-cell landscape of high-grade serous ovarian cancer[J].Nature Medicine,2020,26(8):1271-1279. [6] 张娅,李传应,陈晶晶,等.两种不同免疫组化染色平台TDT及CD10染色效果评价[J].临床与实验病理学杂志,2020,23(3):363-364. [7] Dai J,Cheng Y,Wu J,et al.Modular peptide probe for pre/intra/postoperative therapeutic to reduce recurrence in ovarian cancer[J].ACS nano,2020,14(11):14698-14714. [8] 黄娅芬,周栩茹,李晓兰.KIF23基因沉默对上皮性卵巢癌细胞增殖与迁移和侵袭影响[J].中华肿瘤防治杂志,2019,26(23):35-40. [9] Tew W P,Lacchetti C,Ellis A,et al.PARP inhibitors in the management of ovarian cancer:ASCO guideline[J].Obstetrical & Gynecological Survey,2020,75(12):739-741. [10] 张瑜,吴美琴,涂红勤,等.lncRNAHSD52在卵巢癌组织中的表达及其对卵巢癌细胞增殖和侵袭的影响[J].实用医学杂志,2020,36(7):944-949. [11] Mirza M R,Coleman R L,Gonzalez-Martin A,et al.The forefront of ovarian cancer therapy:update on PARP inhibitors[J].Annals of Oncology,2020,31(9):1148-1159. [12] Iyer S,Zhang S,Yucel S,et al.Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy[J].Cancer Discovery,2021,11(2):384-407. [13] Yarmolinsky J,Bull C J,Vincent E E,et al.Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian cancer[J].Jama,2020,323(7):646-655.